# MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

> **NCT04808323** · PHASE1 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 22 (estimated)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **DRUG:** Capecitabine
- **DEVICE:** Initial Dose of Radiation before Dose Escalation
- **DEVICE:** Cohort A: Dose Escalation Radiation
- **DEVICE:** Cohort B: Dose Escalation Radiation
- **DEVICE:** Cohort C: Dose Escalation Radiation
- **DRUG:** FOLFOX

## Key facts

- **NCT ID:** NCT04808323
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-17
- **Primary completion:** 2027-04-14
- **Final completion:** 2029-01-20
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808323, "MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04808323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*